Lung Cancer

Savolitinib had promising antitumor activity in patients with METex14+ NSCLC and showed acceptable tolerability.
This study reports on the ZENITH20-2 cohort of previously treated patients with advanced NSCLC and an HER2 exon 20 insertion mutation.
Dual treatment with ramucirumab and erlotinib produced similar results in patients with ex21 and ex19 mutations.
Previously untreated patients and those who had received prior intracranial radiotherapy responded to selpercatinib treatment.
Improved progression-free survival and overall survival in patients who received upfront stereotactic radiotherapy and TKI treatment should prompt additional study.
Treatment with dabrafenib and trametinib produced similar benefits in pretreated and treatment-naïve patients.
Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease.
Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations.
Similar progression-free survival and 2-year overall survival rates reported for both treatment groups, with more grade ≥3 treatment-related adverse events reported in the afatinib + cetuximab group.
Ensartinib may be a viable treatment option for some forms of secondary ALK alterations.
Page 2 of 11
Results 11 - 20 of 107